EndoPredict Breast Cancer Prognostic Test – the most accurate second generation prognostic and predictive early-stage breast cancer test

Myriad Genetics’ EndoPredict Breast Cancer Prognostic Test is a gene expression test for early-stage ER-positive/HER2-negative breast cancer. It provides highly accurate prediction of early and up to 15 years risk of distant breast cancer recurrence along with treatment benefit.1-3

This second generation breast cancer test is trusted worldwide to help guide confident adjuvant chemotherapy treatment decisions for pre- and postmenopausal women. EndoPredict also provides information about the long-term risk of distant metastasis after 5 years of endocrine therapy which can guide the decision on whether extended endocrine therapy is needed.

EndoPredict gene expression assay uses molecular biology and clinical pathological factors to provide accurate prognostic insights for early-stage breast cancer

EndoPredict breast cancer test is predictive of adjuvant chemotherapy treatment benefit and prognostic of disease outcome

EndoPredict Breast Cancer Prognostic Test gene expression assay gives an individualized risk assessment to guide critical treatment decisions in early-stage breast cancer:

Can adjuvant chemotherapy be avoided?

EndoPredict breast cancer test supports confident decisions about whether adjuvant chemotherapy can be avoided.1 It gives an accurate risk assessment of distant recurrence at 10 years after 5 years of hormone therapy.

What is the absolute benefit of chemotherapy?

EndoPredict analyzes the absolute benefit of chemotherapy on risk of distant breast cancer recurrence within current treatment regimens.2

Can endocrine therapy be avoided after five years?

EndoPredict helps to decide if extended endocrine therapy for breast cancer can be avoided.3 It is the only gene expression assay that provides late distant recurrence risk up to 15 years.

More prognostic power than other breast cancer tests4,5

EndoPredict combines information about tumor size and nodal status with a gene expression signature that includes genes that predict both early and late breast cancer metastasis. This improves the prognostic power of EndoPredict compared with classical prognostic factors and first generation breast cancer tests.4-6

The higher the Likelihood (x2), the greater the prognostic power

The Likelihood (x2) is a statistical tool used to evaluate the accuracy of an algorithm and therefore the prognostic power of a test by comparing predicted outcomes with actual events. Results are independent of test cut-off values.

Want to know more?

If you are a patient, please talk to your doctor to find out if the EndoPredict breast cancer test is beneficial for you or visit our patient homepage.

If you are a clinician, learn more about the superior prognostic and predictive performance of EndoPredict for early-stage ER-positive/HER2-negative breast cancer.

Trusted worldwide for adjuvant chemotherapy and endocrine therapy treatment planning

Validated in five prospective-retrospective studies with more than 3,500 patients.1-7 First results of a prospective randomized controlled trial (UNIRAD) providing level of evidence (LoE1A) were released at SABCS 2021.8 The first results of an ongoing prospective French registry (SiMoSein) observational study with more than 4,700 patients included by now was presented at ESMO 2021.9

Recommended in many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGTM, AGO, HAS, NICE, SEOM, AIOM, CACA-CBCS, CcO.

Choose EndoPredict for fast, easy, accurate results for every patient

The EndoPredict Breast Cancer Prognosis Test is a CE-marked in vitro diagnostic (IVD) device. It can be performed in local molecular pathology laboratories.

Results are available within a few days.

Accurate – EndoPredict is a second generation test which combines clinical and molecular factors for enhanced prognostic performance, supporting accurate decisions.1

Clinically validated – EndoPredict is clinically validated across more than 3,500 pre- and postmenopausal women1-4,6,7,10 and provides with its latest results LoE 1A.8

Trusted worldwide – EndoPredict is recommended in many international and national guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, EGMT, AGO, HAS, NICE, SEOM, AIOM, CACA-CBS, CcO.

Fast turnaround time – EndoPredict second generation test supports local testing for fast results, with local reimbursement available in selected countries.

References

  1. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors”.Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  2. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone”.Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  3. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only”.Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  4. Buus, Richard et al. “Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy”.Journal Of The National Cancer Institute, vol 108, no. 11, 2016, p. djw149
  5. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer”.JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553
  6. Dubsky, Peter et al. “Endopredict Improves The Prognostic Classification Derived From Common Clinical Guidelines In ER-Positive, HER2-Negative Early Breast Cancer”. Annals Of Oncology, vol 24, no. 3, 2013, pp. 640-647
  7. Constantinidou, Anastasia et al. “Clinical Validation Of Endopredict In Premenopausal Women With Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer.”. Journal Of Clinical Oncology, vol 39, no. 15_suppl, 2021, pp. 537-537
  8. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2-early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9
  9. Lehmann-Che, Jacqueline et al. “Simosein, A Real-Life Prospective Evaluation Of Endopredict Use In Early ER-Positive, HER2-Negative Breast Cancers”. Annals Of Oncology, vol 32, 2021, p. 430
  10. Martin, Miguel et al. “Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2−Breast Cancer Patients: Results From The GEICAM 9906 Trial”.Breast Cancer Research, vol 16, no. 2, 2014, p. R38